Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology

Fairfax, VA US
September 28, 2024

Program Description

This two-day conference aimed at improving the knowledge and competence of academic and community oncology providers involved in Early Phase Clinical Trial Development and Management, Phase I/II Clinical Trials Conduct, and Management of Assessments and Safety Parameters involves more than the development of Concepts.

Recent Phase I Studies involving biomarker-guided design in the era of novel therapies has special challenges in selection of studies, patients’ enrollment along with networking with the surrounding institutions to ensure equity and inclusion of patients enrolled in the early phase studies that direct future drug development.

The activity will use a mix of didactic lectures and panel discussions to highlight various aspects of Early Phase Clinical Studies, Precision oncology, and addressing current challenges and opportunities in designing clinical trials in the era of novel therapies.

In-Person Only

This event is being offered as an in-person conference only.  There will be no virtual piece or recorded sessions.  Attendees will have the opportunity to join the speakers in-person at Inova Center for Personalized Health Conference Center (ICPH) .  

Questions & Refunds

If at any time you have questions, please email: Christina.fontana@inova.org

 

Target Audience

  • Advanced Practice Providers
  • Dietitians
  • Family Medicine
  • Genetic Counselors
  • Internists
  • Medical Oncologists
  • Nurses
  • Nurse Navigators
  • Pharmacists
  • Physicians
  • Radiation Oncologists
  • Radiologists
  • Residents, Students, and Fellows
  • Other Allied Health professionals and Trainees

Learning Objectives

  • Review challenges and trends in early drug development in the era of novel therapies.

  • Outline the best practices for the conduct of Phase I/II clinical trials in the era of novel therapies.

  • Identify phase I clinical trials to match patients’ needs.

  • Review the challenges and potential solutions for the diverse representation during drug development.

Questions about this event?  Contact Christina.fontana@inova.org

Course summary
Available credit: 
  • 3.00 ABIM MOC
  • 11.25 AMA PRA Category 1 Credit™
Course opens: 
03/01/2024
Course expires: 
12/31/2024
Event starts: 
09/28/2024 - 7:00am EDT
Event ends: 
09/28/2024 - 4:45pm EDT
Cost:
$350.00
Add to calendar: 
Rating: 
0

 

Inova Center for Personalized Health Conference Center (ICPH)
8100 Innovation Park Drive
Entrance 3 - front door under Pedestrian Bridge
Fairfax, VA 22301
United States

Parking

Parking is complimentary at the Inova Center for Personalized Health Conference Center (ICPH) . Use surface lots E and F or parking garage for tower C. From the parking garage, take elevator to level 2, walk around the elevators to the bridge over to the conference center. 

Travel

Airports and Ground Transportation

Inova Center for Personalized Health Conference Center (ICPH)  is centrally located between Washington Dulles Airport (IAD) and Reagan Airports (DCA).  Union Station (in Washington, DC) is located about 30-40 minutes from the campus.  Both airports along with Union Station offer onsite ground transportation to Fairfax, VA which is about a 30–40-minute drive.  Uber or Lyft are also reliable ground transportation options in the DC metro area.

Hotels

Below are the two hotels that are located closest to the Inova Center for Personalized Health Conference Center (ICPH) and offer us discounted rates.

8296 Glass Alley, Fairfax, VA 22031

Phone: 571-327-2277

Inova/corporate rate code: 8296INOVA

 

3111 Fairview Park Dr, Falls Church, VA 22042

(703) 849-9400

    Program Director

    Nagla Abdel Karim, MD

    Director of Early Developmental Therapeutics

    Inova Schar Cancer Institute

    Professor of Medicine

    University of Virginia

     

    Advisory Committee:

    • Elad Sharon, MD
    • Rabih Said, MD, MPH

    Drug and Therapeutics Committee:

    • Simona Armanca, PharmD

     

    Speaker Disclosure Statement

    Inova Health System’s Office of Continuing Medical Education adheres to ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, program directors, and planners are required to disclose all relevant financial relationships with ineligible entities as defined by ACCME.  All relevant financial relationships listed for these individuals have been mitigated.  

    Program Director(s)

    Nagla Karim, MD

    has a financial relationship (Contracted Research) with Pfizer;.
    has a financial relationship (Consulting Fee) with AstraZeneca;.
    has a financial relationship (Consulting Fee) with Janssen;.
    has a financial relationship (Consulting Fee) with G1 Therapeutics;.
    has a financial relationship (Consulting Fee) with Jazz Therapeutics;.
    has a financial relationship (Consulting Fee) with Innovent;.
    has a financial relationship (Consulting Fee) with Pfizer;.
    has a financial relationship (Contracted Research) with Exelixis;.
    has a financial relationship (Consulting Fee) with Amgen;.
    has a financial relationship (Consulting Fee) with Sanofi;.
    has a financial relationship (Consulting Fee) with Novocure;.
    has a financial relationship (Professional Services) with Regeneron;.
    has a financial relationship (Contracted Research) with BMS;.
    has a financial relationship (Consulting Fee) with BMS;.
    has a financial relationship (Consulting Fee) with MERCK;.
    has a financial relationship (Consulting Fee) with Immunogen;.
    Speaker(s)

    Germame Ajebo, MD

    has no relevant financial relationships to disclose at this time.

    Laura Alder, MD

    has a financial relationship (Other) with OncoHost ;.
    has a financial relationship (Contracted Research) with BerGenBio;.
    has a financial relationship (Contracted Research) with ORIC;.

    Raid Aljumaily, MD

    has no relevant financial relationships to disclose at this time.

    Simona Armanca, PharmD, BCOP

    has a financial relationship (Other) with Pfizer and Takeda;.

    Minira Aslanova, DO

    has no relevant financial relationships to disclose at this time.

    Nilo Azad

    has no relevant financial relationships to disclose at this time.

    Jennifer Bires, MSW, LCSW, OSW-C

    has no relevant financial relationships to disclose at this time.

    Pamela Brandt, D.O.

    has no relevant financial relationships to disclose at this time.

    Timothy Cannon, MD, Associate Professor at University of Virginia Medical School

    has a financial relationship (Consulting Fee) with Intermountain health care;.

    Katie Chon, PharmD, RPh

    has no relevant financial relationships to disclose at this time.

    Andrew Ciupek, PhD

    has a financial relationship (Consulting Fee) with Novartis;.
    has a financial relationship (Consulting Fee) with Daiichi Sankyo;.
    has a financial relationship (Consulting Fee) with Regeneron;.
    has a financial relationship (Consulting Fee) with Gilead;.
    has a financial relationship (Travel) with Glaxo Smith Kline;.
    has a financial relationship (Consulting Fee) with Seagen;.
    has a financial relationship (Other) with Glaxo Smith Kline;.

    Raymund Cuevo, MD

    has no relevant financial relationships to disclose at this time.

    Ayham Deeb, MD

    has no relevant financial relationships to disclose at this time.

    John Deeken, MD

    has no relevant financial relationships to disclose at this time.

    Jaydira Del Rivero

    has no relevant financial relationships to disclose at this time.

    Chris Draft

    has no relevant financial relationships to disclose at this time.

    Bassel El-Rayes

    has no relevant financial relationships to disclose at this time.

    Lauren Fay, MPH, RD-AP, CSO, CNSC

    has no relevant financial relationships to disclose at this time.

    William Figg, Sr.

    has no relevant financial relationships to disclose at this time.

    Stephanie Gaillard, MD PhD

    has a financial relationship (Grant Or Contract) with Astra-Zeneca;.
    has a financial relationship (Grant Or Contract) with NRG;.
    has a financial relationship (Grant Or Contract) with Immunogen;.
    has a financial relationship (Grant Or Contract) with Volastra;.
    has a financial relationship (Grant Or Contract) with NCTN;.
    has a financial relationship (Grant Or Contract) with Blueprint;.
    has a financial relationship (Other) with Astra-Zeneca;.
    has a financial relationship (Grant Or Contract) with GOG/Clovis/Pharma&;.
    has a financial relationship (Other Securities) with UpToDate;.
    has a financial relationship (Grant Or Contract) with Volastra;.
    has a financial relationship (Grant Or Contract) with Beigene;.
    has a financial relationship (Grant Or Contract) with Compugen;.
    has a financial relationship (Grant Or Contract) with Tempest;.
    has a financial relationship (Grant Or Contract) with MDAnderson;.
    has a financial relationship (Consulting Fee) with Compugen;.

    Joseph Gibbons, M.D>

    has no relevant financial relationships to disclose at this time.

    Aaron Goodman, MD

    has no relevant financial relationships to disclose at this time.

    Krishna Gunturu, Medical Oncologist, MD

    has a financial relationship (Consulting Fee) with BMS;.
    has a financial relationship (Consulting Fee) with Astra Zeneca;.

    Hamza Hashmi, M.D.

    has a financial relationship (Consulting Fee) with Janssen;.
    has a financial relationship (Consulting Fee) with Karyopharm;.
    has a financial relationship (Consulting Fee) with Amgen;.

    Yuxia Jia, MD, PhD

    has no relevant financial relationships to disclose at this time.

    Christopher Johnson, MD, PhD

    has no relevant financial relationships to disclose at this time.

    Nagla Karim, MD

    has a financial relationship (Contracted Research) with Pfizer;.
    has a financial relationship (Consulting Fee) with AstraZeneca;.
    has a financial relationship (Consulting Fee) with Janssen;.
    has a financial relationship (Consulting Fee) with G1 Therapeutics;.
    has a financial relationship (Contracted Research) with Exelixis;.
    has a financial relationship (Consulting Fee) with Jazz Therapeutics;.
    has a financial relationship (Consulting Fee) with Innovent;.
    has a financial relationship (Consulting Fee) with Pfizer;.
    has a financial relationship (Professional Services) with Regeneron;.
    has a financial relationship (Consulting Fee) with Amgen;.
    has a financial relationship (Consulting Fee) with Sanofi;.
    has a financial relationship (Consulting Fee) with Novocure;.
    has a financial relationship (Contracted Research) with BMS;.
    has a financial relationship (Consulting Fee) with BMS;.
    has a financial relationship (Consulting Fee) with MERCK;.
    has a financial relationship (Consulting Fee) with Immunogen;.

    Maya Khalil, MD

    has a financial relationship (Professional Services) with Other - Shanghai Henlius;.
    has a financial relationship (Professional Services) with Other - Numab Therapeutics;.
    has a financial relationship (Professional Services) with Other - I-Mab Biopharma;.
    has a financial relationship (Professional Services) with Abbvie, Inc.;.
    has a financial relationship (Professional Services) with Caris Life Sciences;.
    has a financial relationship (Professional Services) with Boehringer Ingelheim GmbH;.
    has a financial relationship (Professional Services) with Other - Jounce Therapeutics;.
    has a financial relationship (Professional Services) with Merck & Co., Inc.;.
    has a financial relationship (Professional Services) with Regeneron Pharmactcls;.
    has a financial relationship (Professional Services) with National Cancer Institute;.
    has a financial relationship (Professional Services) with Other - Black Diamond Therapeutics;.
    has a financial relationship (Professional Services) with Amgen;.
    has a financial relationship (Professional Services) with SeaGen;.
    has a financial relationship (Professional Services) with Other - Cantargia;.
    has a financial relationship (Professional Services) with Janssen Pharmaceutica Products, LP;.
    has a financial relationship (Professional Services) with Eli Lilly and Company;.
    has a financial relationship (Professional Services) with Other - TopAlliance Biosciences;.
    has a financial relationship (Professional Services) with Other - Xencor;.
    has a financial relationship (Professional Services) with Other - Summit;.
    has a financial relationship (Professional Services) with Bristol Myers Squibb;.
    has a financial relationship (Professional Services) with Other - Navire Pharma inc;.
    has a financial relationship (Professional Services) with Other - Guardant;.
    has a financial relationship (Professional Services) with Spectrum Pharmaceuticals, Inc;.
    has a financial relationship (Professional Services) with BeiGene;.
    has a financial relationship (Professional Services) with AstraZeneca Pharmaceuticals LP;.
    has a financial relationship (Professional Services) with Advenchen Pharmaceuticals, LLC;.
    has a financial relationship (Professional Services) with Taiho Pharmaceuticals Co., Ltd.;.
    has a financial relationship (Professional Services) with Other - NGM Pharmaceuticals;.
    has a financial relationship (Professional Services) with Johnson & Johnson;.
    has a financial relationship (Professional Services) with Other - Dynamicure Biotech;.
    has a financial relationship (Professional Services) with Other - Nitto BioPharma;.
    has a financial relationship (Professional Services) with Astellas Pharma US, Inc;.
    has a financial relationship (Professional Services) with Genentech, Inc;.
    has a financial relationship (Professional Services) with Other - ARCUS BioSciences;.
    has a financial relationship (Professional Services) with Other - Innate Pharma;.
    has a financial relationship (Professional Services) with Other - Debiopharm Group;.
    has a financial relationship (Professional Services) with Takeda Pharmaceuticals North America, Inc.;.

    Chul Kim, MD

    has a financial relationship (Consulting Fee) with Arcus, AstraZeneca, Daiichi Sankyo, Eisai, Regeneron, Sanofi, Takeda, J&J, Pinetree, Boehringer Ingelheim, Gencurix;.
    has a financial relationship (Contracted Research) with AstraZeneca, Novartis, Regeneron, Janssen, Genentech, Lyell, Daiichi Sankyo, Gilead, Macrogenics, Boehringer Ingelheim, Black Diamond Therapeutics;.

    Heejong Kim

    has no relevant financial relationships to disclose at this time.

    So Yeon Kim, MD

    has a financial relationship (Contracted Research) with Astrazencea;.
    has a financial relationship (Consulting Fee) with Genentech;.

    Chung-Han Lee, MD/PhD

    has no relevant financial relationships to disclose at this time.

    Sami Mansfield, BA, ACSM-CET, PN-1

    has no relevant financial relationships to disclose at this time.

    Daniel Margolis, MD

    has a financial relationship (Consulting Fee) with Promaxo, Inc;.
    has a financial relationship (Other) with Stratagen Bio;.
    has a financial relationship (Consulting Fee) with Guerbet, Inc;.

    Thomas Marron

    has a financial relationship (Consulting Fee) with EMD Serono;.
    has a financial relationship (Consulting Fee) with STORM;.
    has a financial relationship (Consulting Fee) with Avammune;.
    has a financial relationship (Grant Or Contract) with BMS;.
    has a financial relationship (Consulting Fee) with Merck;.
    has a financial relationship (Consulting Fee) with AbbVie;.
    has a financial relationship (Consulting Fee) with Ono;.
    has a financial relationship (Consulting Fee) with Regeneron;.
    has a financial relationship (Consulting Fee) with Geneos;.
    has a financial relationship (Consulting Fee) with FATE;.
    has a financial relationship (Grant Or Contract) with Regeneron;.
    has a financial relationship (Consulting Fee) with Genentech;.
    has a financial relationship (Consulting Fee) with AstraZeneca;.
    has a financial relationship (Consulting Fee) with Astellas;.
    has a financial relationship (Grant Or Contract) with Boehringer Ingelheim;.

    Stephen Medlin, DO

    has a financial relationship (Professional Services) with KITE;.

    Dalia Mobarek, MD

    has no relevant financial relationships to disclose at this time.

    John Morris

    has no relevant financial relationships to disclose at this time.

    Abdul Rafeh Naqash, MD

    has no relevant financial relationships to disclose at this time.

    Nina Neill, MD, MS

    has no relevant financial relationships to disclose at this time.

    Ishan Patel, MD

    has no relevant financial relationships to disclose at this time.

    Michael (Mike) Pishvaian

    has a financial relationship (Other) with Seattle Genetics, Tesaro, Arcus Bio, Ideaya, Repare Tx, Novartis, Pfizer, Merck, Tizonia, Amgen, RenovoRx, Boerhinger Ingelheim, Astellas, Actuate, MEI Pharma, Elevation Oncology, Recursion Pharma;.
    has a financial relationship (Patent) with Perthera;.
    has a financial relationship (Stock) with Perthera;.

    Faran Polani, MD

    has no relevant financial relationships to disclose at this time.

    Srivatsan Raghavan, Srivatsan Raghavan, M.D., Ph.D.

    has a financial relationship (Contracted Research) with Microsoft;.
    has a financial relationship (Stock) with Amgen;.

    Matt Reilley, MD

    has a financial relationship (Grant Or Contract) with Astrazeneca;.
    has a financial relationship (Grant Or Contract) with Surface Oncology;.
    has a financial relationship (Grant Or Contract) with Amgen;.
    has a financial relationship (Professional Services) with Seattle Genetics;.
    has a financial relationship (Grant Or Contract) with Pfizer;.
    has a financial relationship (Grant Or Contract) with Merck;.
    has a financial relationship (Professional Services) with Pfizer;.
    has a financial relationship (Grant Or Contract) with Macrogenics;.
    has a financial relationship (Grant Or Contract) with Xencor;.
    has a financial relationship (Grant Or Contract) with Cardiff Oncology;.
    has a financial relationship (Grant Or Contract) with Takeda;.
    has a financial relationship (Professional Services) with NEJM;.

    Jonathan Riess, MD, MS

    has a financial relationship (Consulting Fee) with Merck;.
    has a financial relationship (Consulting Fee) with Janssen;.
    has a financial relationship (Consulting Fee) with Daiichi Sankyo;.
    has a financial relationship (Consulting Fee) with Sanofi;.
    has a financial relationship (Consulting Fee) with BMS;.
    has a financial relationship (Consulting Fee) with Catalyst;.
    has a financial relationship (Consulting Fee) with Regeneron;.
    has a financial relationship (Consulting Fee) with SeaGen;.
    has a financial relationship (Consulting Fee) with Amgen;.
    has a financial relationship (Consulting Fee) with Roche/Genentech;.

    Estelamari Rodriguez

    has a financial relationship (Consulting Fee) with Janssen (Any division);.
    has a financial relationship (Professional Services) with Amgen;.
    has a financial relationship (Consulting Fee) with OncLive;.
    has a financial relationship (Consulting Fee) with Research to Practice;.
    has a financial relationship (Consulting Fee) with Astra Zeneca;.
    has a financial relationship (Consulting Fee) with Genentech;.

    Radha Rohatgi, MD

    has no relevant financial relationships to disclose at this time.

    Anwaar Saeed, MD

    has a financial relationship (Contracted Research) with AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Arcus therapeutics, and KAHR medical;.
    has a financial relationship (Consulting Fee) with AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, Arcus therapeutics, KAHR medical, and Daiichi Sankyo;.

    Rabih Said, MD, MPH

    has no relevant financial relationships to disclose at this time.

    Bobby Se, MD

    has no relevant financial relationships to disclose at this time.

    Triparna Sen, PhD

    has no relevant financial relationships to disclose at this time.

    Elad Sharon, MD

    has a financial relationship (Consulting Fee) with D.E. Shaw Research ;.
    has a financial relationship (Other) with Mallinckrodt Pharmaceuticals;.

    Noha Soror, MD, MSc

    has no relevant financial relationships to disclose at this time.

    Janakiraman Subramanian, MD, MPH

    has a financial relationship (Professional Services) with Daiichi;.
    has a financial relationship (Professional Services) with Oncohost;.
    has a financial relationship (Professional Services) with Cancer Expert Now;.
    has a financial relationship (Professional Services) with Astra Zeneca;.
    has a financial relationship (Professional Services) with G1 therapeutics;.
    has a financial relationship (Professional Services) with Guidepoint;.
    has a financial relationship (Professional Services) with Janssen;.
    has a financial relationship (Professional Services) with GLG;.
    has a financial relationship (Professional Services) with Regeneron/Sanofi;.
    has a financial relationship (Professional Services) with Jazz Pharma;.
    has a financial relationship (Professional Services) with Pfizer;.

    Kei Suzuki

    has no relevant financial relationships to disclose at this time.

    Brian Van Tine, MD, PhD

    has a financial relationship (Patent) with Accuronix Therapeutics;.
    has a financial relationship (Consulting Fee) with Advenchen;.
    has a financial relationship (Consulting Fee) with Acuta Capital ;.
    has a financial relationship (Professional Services) with Kronos Bio;.
    has a financial relationship (Travel) with Polaris;.
    has a financial relationship (Professional Services) with Iterion Therapeutics, Inc;.
    has a financial relationship (Grant Or Contract) with Polaris;.
    has a financial relationship (Consulting Fee) with EcoR1;.
    has a financial relationship (Consulting Fee) with Boxer Capital LLC;.
    has a financial relationship (Consulting Fee) with Kronos Bio;.
    has a financial relationship (Travel) with Adaptimmune;.
    has a financial relationship (Professional Services) with Agenus;.
    has a financial relationship (Consulting Fee) with Daiichi Sankyo Inc. ;.
    has a financial relationship (Consulting Fee) with Salarius Pharmaceuticals, Inc.,;.
    has a financial relationship (Consulting Fee) with Hinge Bio;.
    has a financial relationship (Professional Services) with Oncology Education;.
    has a financial relationship (Consulting Fee) with PTC Therapuetics;.
    has a financial relationship (Consulting Fee) with Deciphera Pharmaceuticals;.
    has a financial relationship (Consulting Fee) with Putnam;.
    has a financial relationship (Consulting Fee) with Aadi;.
    has a financial relationship (Professional Services) with Total Health Conference;.
    has a financial relationship (Consulting Fee) with Boehringer Ingelheim;.
    has a financial relationship (Professional Services) with Curis;.

    Raymond Wadlow, MD

    has a financial relationship (Consulting Fee) with Taiho;.
    has a financial relationship (Consulting Fee) with Exact Sciences;.
    has a financial relationship (Consulting Fee) with Bristol Myers Squibb;.
    has a financial relationship (Consulting Fee) with Pfizer;.
    has a financial relationship (Consulting Fee) with Seagen;.

    Inova CME Accreditation

    The Medical Society of Virginia is a member of the Southern States CME Collaborative, an ACCME Recognized Accreditor. Inova Health System Office of Continuing Medical Education is accredited by the Southern States CME Collaborative to provide continuing medical education for physicians.

    Credit Designation

    The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 11.25 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 11.25 credits in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.

     

    Pharmacy Credit

    VSHP accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 5.25 contact hours (0.525 CEU) submitted to CPE Monitor as early as 1 day after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days. 

    UAN  #0108-9999-24-083-L01-P

    Link to Claim Pharma Credits Opens, Saturday, Sept. 28 at 12:30pm ET: https://www.lecturepanda.com/a/24september28-inova

     

    ABIM MOC

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nurse Credentialing FAQs

    For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME.  For more information visit, https://www.nursingworld.org/certification/faqs/

     

    Available Credit

    • 3.00 ABIM MOC
    • 11.25 AMA PRA Category 1 Credit™

    Thank you Exhibitors! Our event would not be possible without the generous support from our sponsors.

    • Abbvie Oncology
    • Accord BioPharma
    • Agios
    • Alexion Pharmaceuticals
    • Amgen
    • AstraZeneca Oncology
    • Boehringer Ingelheim - Medical
    • Bristol-Meyers Squibb
    • Daiichi Sankyo
    • Eisai
    • EMD Serono
    • Exelixis
    • Genentech, Inc.
    • Gilead
    • Incyte
    • Jazz Pharmaceuticals, Inc.
    • Lantheus
    • Lilly - A Medicine Company
    • Merck
    • Mirati Therapeutics
    • Natera
    • OncoHost
    • Pfizer Oncology, Lung Cancer
    • Pfizer, Inc.
    • Pharmacosmos Therapeutics, Inc.
    • Regeneron
    • Servier Pharmaceuticals
    • Taiho Oncology, Inc.
    • Takeda Oncology
    • Tempus AI
    • Yunu

     

    Interested in Exhibiting? 

    To confirm your space as an exhibitor, complete the exhibitor registration form and return to Christina.Fontana@inova.org. 

    General Exhibit Booth: $3,000

    • 6' undraped table with two chairs
    • Conference registration for two representatives
    • Verbal recognition the day of the conference with signage, podium mention
    • and on screen during the conference
    • Company name on:
      • Exhibitor page on event website
      • Marketing emails
      • Introduction slides, break slides, and closing slides
      • Post-event follow-up attendee email

     

    Premium Exhibitor Booth: $4,500

    • 6' undraped table with two chairs
    • Conference registration for three representatives
    • Access to sit-in on educational sessions
    • Verbal recognition the day of the conference with signage, podium mention
    • and on screen during the conference
    • Company name on:
      • Exhibitor page on event website
      • Marketing emails
      • Introduction slides, break slides, and closing slides
      • Post-event follow-up attendee email
    • Attendee registration list

     

    Nonprofit Organizations Booth - $500

    (501c3 must be submitted for approval)

    • 6' undraped table with two chairs
    • Conference registration for two representatives
    • Verbal recognition the day of the conference with signage, podium mention
    • and on screen during the conference
    • Company name on:
      • Exhibitor page on event website
      • Marketing emails
      • Introduction slides, break slides, and closing slides
      • Post-event follow-up attendee email

    Download the full prospectus here!  PDF icon <span style="color:#3498db">Evolving Therapies September 2024 PROSPECTUS FORM.pdf</span>

    Questions?  Email Christina Fontana for more information. 

     

    Price

    Cost:
    $350.00
    Please login or register to take this course.

    Registration Information:

    In order to view all the event information, please sign in or create an account.